AIM ImmunoTech Inc. Stock News

AIM ImmunoTech (NYSE: AIM) is one of 236 public companies in the Biological products, except diagnostic industry, but how does it weigh in compared to its rivals? We will compare AIM ImmunoTech to related companies based on the strength of its earnings, analyst recommendations, profitability, valuation, dividends, risk and institutional ownership. Insider & Institutional Ownership []

Vanguard Group Inc. grew its holdings in shares of AIM ImmunoTech Inc. (NYSE:AIM) by 3.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,993,156 shares of the companys stock after acquiring an additional 66,757 shares during the quarter. Vanguard Group Inc. owned 4.17% of []

AIM ImmunoTech (NYSE:AIM) announced its earnings results on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Thomson Reuters consensus estimate of ($0.08), Fidelity Earnings reports. AIM ImmunoTech had a negative net margin of 13,662.70% and a negative return on equity of 26.80%. AIM opened at $1.59 on Thursday. AIM []

AIM ImmunoTech (NYSE:AIM) issued its quarterly earnings results on Tuesday. The company reported ($0.08) EPS for the quarter, hitting analysts consensus estimates of ($0.08), Fidelity Earnings reports. AIM ImmunoTech had a negative return on equity of 26.09% and a negative net margin of 12,941.86%. AIM traded down $0.01 during trading on Wednesday, reaching $1.63. 10 []

OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update.

AIM ImmunoTech Inc (NYSE:AIM) closed its third quarter with a $53.7 million balance sheet as the company advances Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer.

AIM ImmunoTech (NYSE: AIM) is one of 232 publicly-traded companies in the Biological products, except diagnostic industry, but how does it contrast to its competitors? We will compare AIM ImmunoTech to related companies based on the strength of its dividends, risk, analyst recommendations, institutional ownership, valuation, earnings and profitability. Insider & Institutional Ownership 15.1% of []

AIM ImmunoTech Inc said it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the US Food and Drug Administration (FDA) for a planne

OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying applicat

AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no severe adverse events" and that the drug was "gener

OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company's belief that its d

AIM ImmunoTech Inc announced that it has finalized the protocol for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The company expec

Finalizes and reports Phase 2 study protocol

Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of

AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis against respiratory viruses. The HCT